Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 5
2008 5
2009 6
2010 9
2011 12
2012 17
2013 20
2014 13
2015 10
2016 14
2017 20
2018 17
2019 27
2020 27
2021 28
2022 42
2023 31
2024 14

Text availability

Article attribute

Article type

Publication date

Search Results

283 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean yukai wang (170 results)?
Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment.
Bock AM, Nowakowski GS, Wang Y. Bock AM, et al. Among authors: wang y. Curr Treat Options Oncol. 2022 Feb;23(2):155-170. doi: 10.1007/s11864-021-00925-1. Epub 2022 Feb 19. Curr Treat Options Oncol. 2022. PMID: 35182296 Review.
Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma.
Wang ML, Jurczak W, Zinzani PL, Eyre TA, Cheah CY, Ujjani CS, Koh Y, Izutsu K, Gerson JN, Flinn I, Tessoulin B, Alencar AJ, Ma S, Lewis D, Lech-Maranda E, Rhodes J, Patel K, Maddocks K, Lamanna N, Wang Y, Tam CS, Munir T, Nagai H, Hernandez-Ilizaliturri F, Kumar A, Fenske TS, Seymour JF, Zelenetz AD, Nair B, Tsai DE, Balbas M, Walgren RA, Abada P, Wang C, Zhao J, Mato AR, Shah NN. Wang ML, et al. Among authors: wang y. J Clin Oncol. 2023 Aug 20;41(24):3988-3997. doi: 10.1200/JCO.23.00562. Epub 2023 May 16. J Clin Oncol. 2023. PMID: 37192437 Free PMC article.
Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium.
Wang Y, Jain P, Locke FL, Maurer MJ, Frank MJ, Munoz JL, Dahiya S, Beitinjaneh AM, Jacobs MT, Mcguirk JP, Vose JM, Goy A, Andreadis C, Hill BT, Dorritie KA, Oluwole OO, Deol A, Paludo J, Shah B, Wang T, Banerjee R, Miklos DB, Rapoport AP, Lekakis L, Ghobadi A, Neelapu SS, Lin Y, Wang ML, Jain MD. Wang Y, et al. J Clin Oncol. 2023 May 10;41(14):2594-2606. doi: 10.1200/JCO.22.01797. Epub 2023 Feb 8. J Clin Oncol. 2023. PMID: 36753699
Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis.
Wang Y, Zhou S, Yang F, Qi X, Wang X, Guan X, Shen C, Duma N, Vera Aguilera J, Chintakuntlawar A, Price KA, Molina JR, Pagliaro LC, Halfdanarson TR, Grothey A, Markovic SN, Nowakowski GS, Ansell SM, Wang ML. Wang Y, et al. JAMA Oncol. 2019 Jul 1;5(7):1008-1019. doi: 10.1001/jamaoncol.2019.0393. JAMA Oncol. 2019. PMID: 31021376 Free PMC article.
Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma.
Salles G, Schuster SJ, Dreyling M, Fischer L, Kuruvilla J, Patten PEM, von Tresckow B, Smith SM, Jiménez-Ubieto A, Davis KL, Anjos C, Chu J, Zhang J, Lobetti Bodoni C, Thieblemont C, Fowler NH, Dickinson M, Martínez-López J, Wang Y, Link BK. Salles G, et al. Among authors: wang y. Blood Adv. 2022 Nov 22;6(22):5835-5843. doi: 10.1182/bloodadvances.2022008150. Blood Adv. 2022. PMID: 35973192 Free PMC article. Clinical Trial.
Clinical and Functional Characterization of Atypical KRAS/NRAS Mutations in Metastatic Colorectal Cancer.
Loree JM, Wang Y, Syed MA, Sorokin AV, Coker O, Xiu J, Weinberg BA, Vanderwalde AM, Tesfaye A, Raymond VM, Miron B, Tarcic G, Zelichov O, Broaddus RR, Ng PKS, Jeong KJ, Tsang YH, Mills GB, Overman MJ, Grothey A, Marshall JL, Kopetz S. Loree JM, et al. Among authors: wang y. Clin Cancer Res. 2021 Aug 15;27(16):4587-4598. doi: 10.1158/1078-0432.CCR-21-0180. Epub 2021 Jun 11. Clin Cancer Res. 2021. PMID: 34117033 Free PMC article.
The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma.
Rejeski K, Hansen DK, Bansal R, Sesques P, Ailawadhi S, Logue JM, Bräunlein E, Cordas Dos Santos DM, Freeman CL, Alsina M, Theurich S, Wang Y, Krackhardt AM, Locke FL, Bachy E, Jain MD, Lin Y, Subklewe M. Rejeski K, et al. Among authors: wang y. J Hematol Oncol. 2023 Jul 31;16(1):88. doi: 10.1186/s13045-023-01465-x. J Hematol Oncol. 2023. PMID: 37525244 Free PMC article.
283 results